Trust Co. of Oklahoma Sells 141 Shares of Eli Lilly and Company (NYSE:LLY)

Trust Co. of Oklahoma lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 22.4% during the third quarter, Holdings Channel.com reports. The institutional investor owned 489 shares of the company’s stock after selling 141 shares during the quarter. Trust Co. of Oklahoma’s holdings in Eli Lilly and Company were worth $433,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in LLY. Scarborough Advisors LLC boosted its holdings in Eli Lilly and Company by 7.4% during the fourth quarter. Scarborough Advisors LLC now owns 465 shares of the company’s stock worth $271,000 after buying an additional 32 shares during the last quarter. Richardson Financial Services Inc. bought a new position in Eli Lilly and Company during the fourth quarter worth about $43,000. Warren Street Wealth Advisors LLC boosted its holdings in Eli Lilly and Company by 15.4% during the fourth quarter. Warren Street Wealth Advisors LLC now owns 964 shares of the company’s stock worth $562,000 after buying an additional 129 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in shares of Eli Lilly and Company by 38.6% during the 4th quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 417,700 shares of the company’s stock valued at $243,486,000 after purchasing an additional 116,300 shares in the last quarter. Finally, Livelsberger Financial Advisory bought a new position in shares of Eli Lilly and Company during the 4th quarter valued at about $135,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 1.9 %

Shares of NYSE:LLY traded down $17.48 during trading on Tuesday, hitting $912.03. 1,454,833 shares of the company were exchanged, compared to its average volume of 2,994,412. The stock has a market cap of $866.80 billion, a price-to-earnings ratio of 134.14, a P/E/G ratio of 2.79 and a beta of 0.42. Eli Lilly and Company has a fifty-two week low of $547.61 and a fifty-two week high of $972.53. The firm has a fifty day moving average price of $913.95 and a two-hundred day moving average price of $854.46. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping the consensus estimate of $2.64 by $1.28. The firm had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. As a group, research analysts anticipate that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on LLY. Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 price objective on shares of Eli Lilly and Company in a report on Monday, September 16th. Berenberg Bank lifted their price objective on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. JPMorgan Chase & Co. lifted their price objective on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a report on Friday, September 13th. BMO Capital Markets lifted their price objective on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $1,025.00 price objective on shares of Eli Lilly and Company in a report on Thursday, October 3rd. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $979.29.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.